News

McKesson's Scott Mooney discusses the technical and operational challenges of DSCSA compliance, from linking ERP systems to EPCIS to recurring friction in 340B transaction data exchange.

HDA's Kala Shankle says a two-year national licensure runway for distributors could work, but only if states, the FDA and industry move in parallel.

Pharmacy directors are using the growing number of publicly visible drug prices as leverage, new research shows. Manufacturers need to be ready, before those prices become a negotiation tool.

The acquisition formalizes a nearly decade-old partnership as independent pharmacies lean on cooperatives to offset PBM reimbursement pressure and closures.

Cardinal Health's Liberty Dewey breaks down the NDC-12 transition timeline and the vendor, association and wholesaler support smaller pharmacies will need to get ready.

As loss-of-exclusivity events accelerate, generics and biosimilars are diverging into distinct business models, demanding different regulatory, IP, and market access strategies from manufacturers.

Cencora's Gregg Gorniak breaks down what separates basic DSCSA compliance from using it to streamline transactions and strengthen trading partnerships.

Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.

Cencora's Ameer Ali explains how the shift to NDC-12 is reshaping supply chain systems and why readiness still varies widely across manufacturers.

Alexis Cogswell of Inizio Medical explains how combining real-world data, AI analysis and HCP context is helping medical affairs teams move from retrospective reporting to actionable, real-time strategy.

Ahead of HDA's 2026 Traceability Seminar, Cencora's Gregg Gorniak explains how AI and RFID are being used to catch DSCSA data gaps before trucks reach the dock.

In this week's Pharma Pulse, new Medicaid pricing deals are rumored, employer GLP-1 pullback, and McKesson's $2.25B oncology buy.

As pharmaceutical companies scale their use of AI across drug safety operations, the Council for International Organizations of Medical Sciences Working Group XIV's now-published guidance sets the bar for what will be required for sustained system validation.

Cardinal Health's Michelle Britt discusses the policy changes needed to secure independent pharmacy's future, from state advocacy wins to giving pharmacists a seat at the table.

TrumpRx has topped 800 drugs since its February launch, but managed care skepticism over real patient savings persists.

Virtual care's pre- and postvisit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

Vikram Anand explains how connected pharmacovigilance systems improve HCP and patient experiences, and why predictive, AI-driven intake is the next frontier for manufacturers.

Health care's real challenge isn't more data, it's activation. Arcadia's Sandy Leonard on turning real-world evidence into point-of-care action.

Cardinal Health's Michelle Britt discusses how independent pharmacies are expanding clinical services and leaning on distributor partnerships to meet evolving patient and community needs.

AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing claims and pharmacy access hurdles for patients.

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after FDA approval.

In coordination with the Centers for Medicare and Medicaid Services, 10 PBMs will surface TrumpRx cash prices in prescribers' benefit tools, PCMA announced.

JD Power's 2026 U.S. Pharmacy Study shows mail-order satisfaction climbing as brick-and-mortar retailers lose customer trust and perceived value.

In this week's Pharma Pulse, Trump nominates Heidi Overton to lead the FDA, EVERSANA expands its AI-powered commercialization platform into medical affairs and market research, Moderna and Merck's personalized mRNA cancer vaccine clears a landmark Phase 3 trial, and IAG Cargo expands its pharma cold chain network into Kuala Lumpur.

Cardinal Health's Michelle Britt discusses the operating costs, cash flow strain and reimbursement pressures facing independent pharmacies, and how owners are diversifying revenue to stay open.

AI-enabled pharmacovigilance is becoming a commercial capability that protects product value and speeds evidence-based market access decisions.

Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust.

IAG Cargo has added a Kuala Lumpur station to its Constant Climate network, its 13th in Asia-Pacific, as regional biologics and personalized medicine demand accelerates.